JP6214643B2 - ピリミジニルチロシンキナーゼ阻害剤 - Google Patents
ピリミジニルチロシンキナーゼ阻害剤 Download PDFInfo
- Publication number
- JP6214643B2 JP6214643B2 JP2015516256A JP2015516256A JP6214643B2 JP 6214643 B2 JP6214643 B2 JP 6214643B2 JP 2015516256 A JP2015516256 A JP 2015516256A JP 2015516256 A JP2015516256 A JP 2015516256A JP 6214643 B2 JP6214643 B2 JP 6214643B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- acceptable salt
- pharmaceutically acceptable
- amino
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C*C([C@@](CCN(C1)c(ncnc2N)c2F)[C@]1N(CCC[C@]1Nc2cc(Cl)cc(*)c2)C1=O)=O Chemical compound C*C([C@@](CCN(C1)c(ncnc2N)c2F)[C@]1N(CCC[C@]1Nc2cc(Cl)cc(*)c2)C1=O)=O 0.000 description 6
- NNHLHUQUOSCOEN-YSTUSHMSSA-N CN(CC1)CCN1C([C@@H](CCN(C1)c2ncnc(N)c2F)[C@H]1N(CCCC1Nc2cc(Cl)cc(C(F)(F)F)c2)C1=O)=O Chemical compound CN(CC1)CCN1C([C@@H](CCN(C1)c2ncnc(N)c2F)[C@H]1N(CCCC1Nc2cc(Cl)cc(C(F)(F)F)c2)C1=O)=O NNHLHUQUOSCOEN-YSTUSHMSSA-N 0.000 description 1
- XIXPQPAHEZDFNG-WMEOFMBSSA-N CN(CC1)CCN1C([C@@H](CCNC1)[C@H]1N(CCCC1Nc2cc(Cl)cc(C(F)(F)F)c2)C1=O)=O Chemical compound CN(CC1)CCN1C([C@@H](CCNC1)[C@H]1N(CCCC1Nc2cc(Cl)cc(C(F)(F)F)c2)C1=O)=O XIXPQPAHEZDFNG-WMEOFMBSSA-N 0.000 description 1
- GUPKEOUZKHLRGS-HYPNFROTSA-N C[C@@H](c1ccccc1)/N=C(\CN(CC1)c(ncnc2N)c2F)/C1C(O)=O Chemical compound C[C@@H](c1ccccc1)/N=C(\CN(CC1)c(ncnc2N)c2F)/C1C(O)=O GUPKEOUZKHLRGS-HYPNFROTSA-N 0.000 description 1
- SUMCMXORPZCWHU-UHFFFAOYSA-N NC(C1F)=NC=NC1Cl Chemical compound NC(C1F)=NC=NC1Cl SUMCMXORPZCWHU-UHFFFAOYSA-N 0.000 description 1
- OVENUGPMQDFGLE-UHFFFAOYSA-N Nc1cc(Cl)cc(C(F)(F)F)c1 Chemical compound Nc1cc(Cl)cc(C(F)(F)F)c1 OVENUGPMQDFGLE-UHFFFAOYSA-N 0.000 description 1
- FEIFDRDCVMVUJA-UHFFFAOYSA-N Nc1ncnc(Cl)c1F Chemical compound Nc1ncnc(Cl)c1F FEIFDRDCVMVUJA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261657360P | 2012-06-08 | 2012-06-08 | |
| US61/657,360 | 2012-06-08 | ||
| PCT/US2013/044800 WO2013185084A1 (en) | 2012-06-08 | 2013-06-07 | Pyrimidinyl tyrosine kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017150480A Division JP2017193583A (ja) | 2012-06-08 | 2017-08-03 | ピリミジニルチロシンキナーゼ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015518903A JP2015518903A (ja) | 2015-07-06 |
| JP2015518903A5 JP2015518903A5 (cg-RX-API-DMAC7.html) | 2016-07-28 |
| JP6214643B2 true JP6214643B2 (ja) | 2017-10-18 |
Family
ID=49712704
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015516256A Expired - Fee Related JP6214643B2 (ja) | 2012-06-08 | 2013-06-07 | ピリミジニルチロシンキナーゼ阻害剤 |
| JP2017150480A Withdrawn JP2017193583A (ja) | 2012-06-08 | 2017-08-03 | ピリミジニルチロシンキナーゼ阻害剤 |
| JP2019017850A Withdrawn JP2019077728A (ja) | 2012-06-08 | 2019-02-04 | ピリミジニルチロシンキナーゼ阻害剤 |
| JP2021018128A Pending JP2021073299A (ja) | 2012-06-08 | 2021-02-08 | ピリミジニルチロシンキナーゼ阻害剤 |
| JP2021018127A Pending JP2021073298A (ja) | 2012-06-08 | 2021-02-08 | ピリミジニルチロシンキナーゼ阻害剤 |
| JP2023004462A Pending JP2023052415A (ja) | 2012-06-08 | 2023-01-16 | ピリミジニルチロシンキナーゼ阻害剤 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017150480A Withdrawn JP2017193583A (ja) | 2012-06-08 | 2017-08-03 | ピリミジニルチロシンキナーゼ阻害剤 |
| JP2019017850A Withdrawn JP2019077728A (ja) | 2012-06-08 | 2019-02-04 | ピリミジニルチロシンキナーゼ阻害剤 |
| JP2021018128A Pending JP2021073299A (ja) | 2012-06-08 | 2021-02-08 | ピリミジニルチロシンキナーゼ阻害剤 |
| JP2021018127A Pending JP2021073298A (ja) | 2012-06-08 | 2021-02-08 | ピリミジニルチロシンキナーゼ阻害剤 |
| JP2023004462A Pending JP2023052415A (ja) | 2012-06-08 | 2023-01-16 | ピリミジニルチロシンキナーゼ阻害剤 |
Country Status (30)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI557127B (zh) | 2009-09-04 | 2016-11-11 | 百健Ｍａ公司 | 布魯頓氏酪胺酸激酶抑制劑 |
| US9273028B2 (en) | 2010-10-29 | 2016-03-01 | Biogen Ma Inc. | Heterocyclic tyrosine kinase inhibitors |
| AR091273A1 (es) * | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
| US9353087B2 (en) * | 2012-06-08 | 2016-05-31 | Biogen Ma Inc. | Inhibitors of Bruton's tyrosine kinase |
| MY179781A (en) * | 2013-12-11 | 2020-11-13 | Biogen Ma Inc | Biaryl inhibitors of bruton's tyrosine kinase |
| WO2015151006A1 (en) | 2014-03-29 | 2015-10-08 | Lupin Limited | Substituted purine compounds as btk inhibitors |
| WO2015170266A1 (en) | 2014-05-07 | 2015-11-12 | Lupin Limited | Substituted pyrimidine compounds as btk inhibitors |
| HUE050706T2 (hu) * | 2014-10-24 | 2020-12-28 | Bristol Myers Squibb Co | Indol karboxamid vegyületek, amelyek hasznosak kináz inhibitorokként |
| CN110049976A (zh) | 2016-07-21 | 2019-07-23 | 比奥根Ma公司 | 布鲁顿氏酪氨酸激酶抑制剂的琥珀酸盐形式和组合物 |
| JP7331843B2 (ja) | 2018-04-27 | 2023-08-23 | 小野薬品工業株式会社 | Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤 |
| KR102653681B1 (ko) | 2018-07-31 | 2024-04-03 | 록쏘 온콜로지, 인코포레이티드 | (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제 |
| CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
| US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2022140246A1 (en) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| WO2022212893A1 (en) | 2021-04-02 | 2022-10-06 | Biogen Ma Inc. | Combination treatment methods of multiple sclerosis |
| WO2023081709A1 (en) | 2021-11-03 | 2023-05-11 | Viracta Therapeutics, Inc. | Vecabrutinib for the treatment of graft-versus-host disease |
| WO2023081715A1 (en) | 2021-11-03 | 2023-05-11 | Viracta Therapeutics, Inc. | Combination of car t-cell therapy with btk inhibitors and methods of use thereof |
| KR20240157639A (ko) | 2021-12-14 | 2024-11-01 | 크로스파이어 온콜로지 홀딩 비.브이. | 거대고리 btk 억제제 |
| WO2024245577A1 (en) | 2023-06-02 | 2024-12-05 | Netherlands Translational Research Center Holding B.V. | Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor |
| WO2024246287A1 (en) | 2023-06-02 | 2024-12-05 | Crossfire Oncology Holding B.V. | Medical use of a macrocyclic reversible btk inhibitor |
| WO2024245578A1 (en) | 2023-06-02 | 2024-12-05 | Netherlands Translational Research Center Holding B.V. | Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor |
| WO2024256568A1 (en) | 2023-06-13 | 2024-12-19 | Crossfire Oncology Holding B.V. | Salt and crystal forms of a macrocyclic btk inhibitor |
| WO2024256574A1 (en) | 2023-06-13 | 2024-12-19 | Crossfire Oncology Holding B.V. | Process for preparing macrocyclic btk inhibitors |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1624A (en) * | 1840-06-10 | Cooking-stove | ||
| US4528138A (en) | 1984-06-20 | 1985-07-09 | E. R. Squibb & Sons, Inc. | 16-Keto-17-substituted thia-17-alkyl(or alkenyl or alkynyl) androstenes |
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| DK0495421T3 (da) | 1991-01-15 | 1996-12-09 | Alcon Lab Inc | Anvendelse af carragenaner i topiske ophthalmiske sammensætninger |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| US6919178B2 (en) | 2000-11-21 | 2005-07-19 | Sunesis Pharmaceuticals, Inc. | Extended tethering approach for rapid identification of ligands |
| JP2003528072A (ja) | 2000-03-17 | 2003-09-24 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | マトリックスメタロプロテアーゼおよびＴＮＦ−αの阻害剤としての環状β−アミノ酸誘導体 |
| MY145722A (en) | 2000-04-27 | 2012-03-30 | Abbott Lab | Diazabicyclic central nervous system active agents |
| CN100351253C (zh) | 2000-06-26 | 2007-11-28 | 辉瑞产品公司 | 作为免疫抑制剂的吡咯并[2,3－d]嘧啶化合物 |
| PE20020507A1 (es) * | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
| AU2002363236A1 (en) * | 2001-10-30 | 2003-05-12 | Millennium Pharmaceuticals, Inc. | Compounds, pharmaceutical compositions and methods of use therefor |
| EP1442039A1 (en) | 2001-10-31 | 2004-08-04 | Bayer HealthCare AG | Pyrimido (4,5-b) indole derivatives |
| CN102558155A (zh) | 2003-01-14 | 2012-07-11 | 阿伦纳药品公司 | 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗 |
| CA2542076C (en) | 2003-10-14 | 2013-02-26 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Substituted tricyclic compounds as protein kinase inhibitors |
| EP1778298A4 (en) * | 2004-04-01 | 2010-03-31 | Univ Pennsylvania | LIPOPROTEIN-NANO PLATFORMS |
| JP5213229B2 (ja) | 2004-04-23 | 2013-06-19 | エグゼリクシス， インコーポレイテッド | キナーゼ調節因子および使用方法 |
| FR2870541B1 (fr) | 2004-05-18 | 2006-07-14 | Proskelia Sas | Derives de pyrimidines antigonistes du recepteur de la vitronectine |
| TW200621760A (en) | 2004-09-09 | 2006-07-01 | Mitsubishi Pharma Corp | 2-morpholino-4-pyrimidone compound |
| AU2005304784B2 (en) * | 2004-11-04 | 2011-03-24 | Vertex Pharmaceuticals Incorporated | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases |
| EP1819684B1 (en) | 2004-12-03 | 2013-08-07 | Intervet International B.V. | Substituted piperazines as cb1 antagonists |
| CA2590961C (en) | 2004-12-28 | 2013-11-26 | Exelixis, Inc. | [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases |
| WO2006071875A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| US7423043B2 (en) * | 2005-02-18 | 2008-09-09 | Lexicon Pharmaceuticals, Inc. | 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds |
| US20060281700A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators |
| US20060281764A1 (en) | 2005-06-10 | 2006-12-14 | Gaul Michael D | Aminopyrimidines as kinase modulators |
| TW200740779A (en) | 2005-07-22 | 2007-11-01 | Mitsubishi Pharma Corp | Intermediate compound for synthesizing pharmaceutical agent and production method thereof |
| JP5191391B2 (ja) | 2005-11-01 | 2013-05-08 | ターゲジェン インコーポレーティッド | キナーゼのビ−アリールメタ−ピリミジン阻害剤 |
| AU2006331994A1 (en) * | 2005-12-21 | 2007-07-05 | Schering Corporation | Combination of an H3 antagonist/inverse agonist and an appetite suppressant |
| WO2008005368A2 (en) | 2006-06-30 | 2008-01-10 | Abbott Laboratories | Piperazines as p2x7 antagonists |
| WO2008012635A2 (en) | 2006-07-26 | 2008-01-31 | Pfizer Products Inc. | Amine derivatives useful as anticancer agents |
| CA2659605A1 (en) | 2006-07-26 | 2008-01-31 | Novartis Ag | Inhibitors of undecaprenyl pyrophosphate synthase |
| US20100160292A1 (en) | 2006-09-11 | 2010-06-24 | Cgi Pharmaceuticals, Inc | Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors |
| ES2616789T3 (es) | 2006-09-22 | 2017-06-14 | Pharmacyclics, Inc. | Inhibidores de tirosina cinasa de Bruton |
| TW200840571A (en) * | 2007-03-02 | 2008-10-16 | Schering Corp | Piperidine derivatives and methods of use thereof |
| US8188272B2 (en) | 2007-03-21 | 2012-05-29 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| WO2008144253A1 (en) | 2007-05-14 | 2008-11-27 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| JP5291095B2 (ja) | 2007-06-01 | 2013-09-18 | グラクソスミスクライン エルエルシー | イミダゾピリジンキナーゼ阻害剤 |
| WO2009098144A1 (en) * | 2008-02-05 | 2009-08-13 | F. Hoffmann-La Roche Ag | Novel pyridinones and pyridazinones |
| MX343525B (es) | 2008-04-29 | 2016-11-09 | Immunexcite Inc | Composiciones inmunomoduladoras y metodos de uso de las mismas. |
| CN102159214A (zh) | 2008-07-16 | 2011-08-17 | 药品循环公司 | 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂 |
| WO2010068788A1 (en) * | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Heterocyclic amides as btk inhibitors |
| CN102325753B (zh) * | 2008-12-19 | 2014-09-10 | 百时美施贵宝公司 | 用作激酶抑制剂的咔唑甲酰胺化合物 |
| EP3828185B1 (en) * | 2009-01-06 | 2024-11-20 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
| ES2565952T3 (es) | 2009-05-25 | 2016-04-07 | Sandoz Ag | Método para la producción de ceftobiprol medocaril |
| WO2011029043A1 (en) | 2009-09-04 | 2011-03-10 | Biogen Idec Ma Inc. | Heteroaryl btk inhibitors |
| TWI557127B (zh) * | 2009-09-04 | 2016-11-11 | 百健Ｍａ公司 | 布魯頓氏酪胺酸激酶抑制劑 |
| US8685880B2 (en) | 2010-06-30 | 2014-04-01 | Chevron U.S.A. Inc. | On-site drying of aqueous salt for ionic liquid make-up |
| US9273028B2 (en) | 2010-10-29 | 2016-03-01 | Biogen Ma Inc. | Heterocyclic tyrosine kinase inhibitors |
| US9353087B2 (en) | 2012-06-08 | 2016-05-31 | Biogen Ma Inc. | Inhibitors of Bruton's tyrosine kinase |
| AR091273A1 (es) * | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
| MY179781A (en) | 2013-12-11 | 2020-11-13 | Biogen Ma Inc | Biaryl inhibitors of bruton's tyrosine kinase |
| WO2015089327A1 (en) | 2013-12-11 | 2015-06-18 | Biogen Idec Ma Inc. | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
| WO2016054627A1 (en) | 2014-10-03 | 2016-04-07 | Ohio State Innovation Foundation | Biomarkers of bruton tyrosine kinase inhibitor resistance |
| CN110049976A (zh) * | 2016-07-21 | 2019-07-23 | 比奥根Ma公司 | 布鲁顿氏酪氨酸激酶抑制剂的琥珀酸盐形式和组合物 |
-
2013
- 2013-06-05 AR ARP130101980 patent/AR091273A1/es not_active Application Discontinuation
- 2013-06-07 MX MX2014015044A patent/MX363672B/es unknown
- 2013-06-07 BR BR122021002178-3A patent/BR122021002178B1/pt active IP Right Grant
- 2013-06-07 WO PCT/US2013/044800 patent/WO2013185084A1/en not_active Ceased
- 2013-06-07 TW TW110102365A patent/TWI792158B/zh not_active IP Right Cessation
- 2013-06-07 KR KR1020227039393A patent/KR20220154850A/ko not_active Ceased
- 2013-06-07 EP EP13800042.7A patent/EP2858499B1/en active Active
- 2013-06-07 CA CA3108186A patent/CA3108186A1/en not_active Abandoned
- 2013-06-07 PT PT13800042T patent/PT2858499T/pt unknown
- 2013-06-07 EA EA201492056A patent/EA027823B1/ru unknown
- 2013-06-07 EP EP20186539.1A patent/EP3753934A1/en not_active Withdrawn
- 2013-06-07 CN CN201810384098.3A patent/CN109305959B/zh active Active
- 2013-06-07 ES ES18171833T patent/ES2834333T3/es active Active
- 2013-06-07 ES ES13800042.7T patent/ES2684268T3/es active Active
- 2013-06-07 EP EP18171833.9A patent/EP3385263B1/en not_active Not-in-force
- 2013-06-07 KR KR1020207010675A patent/KR20200043497A/ko not_active Ceased
- 2013-06-07 LT LTEP13800042.7T patent/LT2858499T/lt unknown
- 2013-06-07 SI SI201331130T patent/SI2858499T1/sl unknown
- 2013-06-07 SG SG10201708535UA patent/SG10201708535UA/en unknown
- 2013-06-07 HR HRP20181294TT patent/HRP20181294T1/hr unknown
- 2013-06-07 NZ NZ702715A patent/NZ702715A/en not_active IP Right Cessation
- 2013-06-07 SG SG11201408173WA patent/SG11201408173WA/en unknown
- 2013-06-07 RS RS20180950A patent/RS57978B1/sr unknown
- 2013-06-07 IN IN10576DEN2014 patent/IN2014DN10576A/en unknown
- 2013-06-07 HU HUE13800042A patent/HUE039897T2/hu unknown
- 2013-06-07 BR BR112014030655-9A patent/BR112014030655B1/pt not_active IP Right Cessation
- 2013-06-07 PH PH1/2018/501463A patent/PH12018501463B1/en unknown
- 2013-06-07 KR KR1020217017552A patent/KR102468430B1/ko active Active
- 2013-06-07 CA CA2875799A patent/CA2875799C/en active Active
- 2013-06-07 KR KR1020157000393A patent/KR102102587B1/ko not_active Expired - Fee Related
- 2013-06-07 PL PL13800042T patent/PL2858499T3/pl unknown
- 2013-06-07 DK DK13800042.7T patent/DK2858499T3/en active
- 2013-06-07 CN CN201380036869.5A patent/CN104540385B/zh not_active Expired - Fee Related
- 2013-06-07 CN CN202110783143.4A patent/CN113549055A/zh active Pending
- 2013-06-07 TW TW106116775A patent/TWI719209B/zh not_active IP Right Cessation
- 2013-06-07 EA EA201790418A patent/EA201790418A1/ru unknown
- 2013-06-07 MX MX2019003618A patent/MX385593B/es unknown
- 2013-06-07 AU AU2013271407A patent/AU2013271407B2/en not_active Ceased
- 2013-06-07 TW TW102120447A patent/TWI592406B/zh not_active IP Right Cessation
- 2013-06-07 US US14/406,315 patent/US9394277B2/en active Active
- 2013-06-07 JP JP2015516256A patent/JP6214643B2/ja not_active Expired - Fee Related
- 2013-06-08 SM SM20180442T patent/SMT201800442T1/it unknown
-
2014
- 2014-11-27 IL IL235938A patent/IL235938B/en active IP Right Grant
- 2014-12-03 PH PH12014502699A patent/PH12014502699A1/en unknown
- 2014-12-15 ZA ZA2014/09255A patent/ZA201409255B/en unknown
-
2016
- 2016-06-29 US US15/196,389 patent/US9944622B2/en active Active
-
2017
- 2017-03-07 AU AU2017201536A patent/AU2017201536B2/en not_active Ceased
- 2017-08-03 JP JP2017150480A patent/JP2017193583A/ja not_active Withdrawn
-
2018
- 2018-03-05 US US15/911,546 patent/US10618887B2/en active Active
- 2018-08-16 CY CY181100861T patent/CY1120638T1/el unknown
-
2019
- 2019-02-04 JP JP2019017850A patent/JP2019077728A/ja not_active Withdrawn
- 2019-05-17 AU AU2019203476A patent/AU2019203476B2/en not_active Ceased
-
2020
- 2020-02-27 US US16/802,959 patent/US20210017155A1/en not_active Abandoned
- 2020-10-11 IL IL277951A patent/IL277951A/en unknown
-
2021
- 2021-02-08 JP JP2021018128A patent/JP2021073299A/ja active Pending
- 2021-02-08 JP JP2021018127A patent/JP2021073298A/ja active Pending
- 2021-04-21 AU AU2021202412A patent/AU2021202412A1/en not_active Abandoned
-
2022
- 2022-08-08 US US17/883,202 patent/US20230174511A1/en not_active Abandoned
- 2022-11-25 AU AU2022275504A patent/AU2022275504A1/en not_active Abandoned
-
2023
- 2023-01-16 JP JP2023004462A patent/JP2023052415A/ja active Pending
-
2024
- 2024-08-23 US US18/813,750 patent/US20240417389A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6214643B2 (ja) | ピリミジニルチロシンキナーゼ阻害剤 | |
| HK40043767A (en) | Pyrimidinyl derivatives useful as tyrosine kinase inhibitors | |
| HK1262106B (en) | Pyrimidinyl tyrosine kinase inhibitors | |
| HK1262106A1 (en) | Pyrimidinyl tyrosine kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160606 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160606 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170207 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170209 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170501 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170706 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170803 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170824 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170919 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6214643 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |